CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.
Company profile
Ticker
CPMD
Exchange
CEO
Dominick Colvin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CAVION TECHNOLOGIES INC, CCVG, INC., CONCORD VENTURES, INC., GOLDEN DRAGON HOLDING CO.
SEC CIK
Corporate docs
IRS number
274635140
CPMD stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
26 Mar 24
8-K/A
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
22 Feb 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Entry into a Material Definitive Agreement
6 Dec 23
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
Changes in Registrant's Certifying Accountant
13 Nov 23
8-K
Departure of Directors or Certain Officers
13 Oct 23
10-Q
2023 Q2
Quarterly report
13 Oct 23
10-Q
2023 Q1
Quarterly report
22 Sep 23
Latest ownership filings
3
Anthony Michael Panek
3 Oct 23
4
JAMES F SAMUELSON
26 Jun 20
4
Matthew Nicosia
19 Jun 20
3/A
Dominic Colvin
29 Apr 20
4
Dominic Colvin
29 Apr 20
3/A
Dominic Colvin
29 Apr 20
3
MARC R BRANSON
29 Apr 20
3
John Hamilton Cassels
4 Feb 20
3
Andrew Clifford Steedman
4 Feb 20
4/A
JAMES F SAMUELSON
3 Feb 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | ||||||
Cash burn (monthly) | (no burn) | 625.17 | 222.50 k | 633.26 k | (no burn) | 171.79 k |
Cash used (since last report) | n/a | 4.18 k | 1.49 mm | 4.23 mm | n/a | 1.15 mm |
Cash remaining | n/a | -4.18 k | -1.49 mm | -4.23 mm | n/a | -1.15 mm |
Runway (months of cash) | n/a | -6.7 | -6.7 | -6.7 | n/a | -6.7 |
Press releases
CannapharmaRx Pays Off Convertible Notes
2 Apr 24
CannapharmaRx Receives First Purchase Order and Begins Shipment of Product
14 Mar 24
CannaPharmaRx Completes First Harvests
12 Mar 24
CannaPharmaRx to Hold Investor Conference Call
7 Mar 24
CannaPharmaRx Executes Multi-Year Supply Agreement with ICAN to Create Distribution Network in the Latin Americas
5 Mar 24